Biohaven Ltd.
NYSE:BHVNBiotechnology
-$0.22 today
- Market cap
- $1.95B
- Beta
- 3.31
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$4.39
Volume 2.32M
Average 2.47M
BHVN Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Biohaven Ltd.NYSE: BHVN
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin declines year over year
Q2 FY2026 selling, general & admin of $24.09M fell 11.9% year over year, behind the -4.4% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 9.5% from the prior quarter. Over 3 fiscal years it compounded at -6.7% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 8 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +19.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $24.09M-9.5% QoQ
- Last fiscal yearDec 2025
- $106.17M+19.0% YoY
- LTMJun 2026
- $99.69M-4.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -11.9% | -100.0% | -88.1 pp |
| 1 year | +19.0% | -100.0% | -119.0 pp |
| 3-year CAGR | -6.7% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 106.17M USD
- Year-over-year change
- +19.0%
- 4-year CAGR
- +29.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 106.17M | +19.0% |
| FY2024 | 2024-12-31 | 89.24M | +42.2% |
| FY2023 | 2023-12-31 | 62.77M | -52.0% |
| FY2022 | 2022-12-31 | 130.86M | +249.8% |
| FY2021 | 2021-12-31 | 37.41M | — |
Selling, General & Admin vs competitors
How BHVN compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -4.4% is the 10th highest of 11, against a peer median of +26.4%.
- Over three fiscal years its annual growth of -6.7% compares with a peer median of +17.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $191.5M USD | +13.2% | +9.8% | 60.8% | |
| LTM Mar 2026 | $157.94M USD | +14.5% | +9.9% | 239.0% | |
| LTM Jun 2026 | $153.89M USD | +144.6% | +66.0% | — | |
| LTM Mar 2026 | $151.41M USD | -3.4% | — | 39.2% | |
| LTM Jun 2026 | $99.69M USD | -4.4% | -6.7% | — | |
| LTM Sep 2026 | $64.15M USD | +52.3% | +47.5% | — | |
| LTM Sep 2026 | €61.14M EUR | +31.2% | +15.6% | — | |
| LTM Mar 2026 | $57.81M USD | +55.3% | +58.0% | — | |
| LTM Sep 2026 | $53.4M USD | -37.3% | +4.7% | 78.7% | |
| LTM Sep 2026 | $51.3M USD | +21.7% | +17.2% | 45802.7% | |
| LTM Mar 2026 | $34.12M USD | +106.9% | +61.9% | — | |
| Peer median (excluding BHVN) | — | +26.4% | +17.2% | 78.7% | |
Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.14M |
| Gross Profit | 0 | 0 | 0 | 0 | (4.14M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 181.49M | 437.07M | 373.28M | 795.87M | 635.07M |
| Selling, General & Admin | 37.41M | 130.86M | 62.77M | 89.24M | 106.17M |
| Operating Expenses | 218.9M | 567.93M | 436.05M | 885.11M | 741.24M |
| Depreciation & Amortization | 1.39M | 1.39M | 6.91M | 7.86M | 9.92M |
| EBITDA | (211.04M) | (568.46M) | (402.64M) | (837.83M) | (727.46M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (218.9M) | (567.93M) | (436.05M) | (885.11M) | (745.38M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 17.73M | 21.33M | 14.59M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 6.47M | (1.91M) | 26.5M | 39.42M | 8M |
| Income Before Tax | (212.43M) | (569.84M) | (409.55M) | (845.69M) | (737.38M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1.37M | 438K | (1.38M) | 735K | 1.44M |
| Net Income | (213.8M) | (570.28M) | (408.17M) | (846.42M) | (738.82M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (5.97) | (12.75) | (5.73) | (9.28) | (6.86) |
| EPS (Diluted) | (5.97) | (12.75) | (5.73) | (9.28) | (6.86) |
| Weighted Avg Shares | 35.82M | 44.74M | 71.2M | 91.23M | 107.62M |
| Weighted Avg Shares (Diluted) | 35.82M | 44.74M | 71.2M | 91.23M | 107.62M |
Biohaven Ltd.
NYSE:BHVN
Intrinsic Alpha fair value
Locked
Current Price
$12.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.